TLX Stock Analysis: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$11.33
-1.09 (-8.78%)
âŧ
5d:
-4.15%
30d:
+7.8%
90d:
+10.32%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 02, 2026
0d
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TLX is fairly priced but lacks strong directional signals. At 24.9% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TLX is fairly priced but lacks strong directional signals. At 24.9% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.14
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $11.33, which is considered fair relative to its 30-day fair value range of $10.17 to $11.80. From a valuation perspective, the stock is trading at a premium (Forward PE: 55.8) compared to its historical average (28.6). At these levels, the market is pricing in 24.9% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $11.19. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.8% recently.
Market Sentiment: TLX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.14 (+86.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $11.19. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.8% recently.
Market Sentiment: TLX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.14 (+86.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$10.17 -
$11.80
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
40.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.8%)
- BULLISH: Trading 86.5% below Wall St target ($21.14)
- BEARISH: Market expects 24.9% growth - appears too optimistic based on history
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.17 -
$11.80
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$11.19
Resistance Level
$12.48
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
55.81
Wall Street Target
$21.14
(+86.5%)
Revenue Growth (YoY)
49.3%
Profit Margin
-0.9%
Valuation Premium vs History
+24.9% premium
PE vs Historical
55.8 vs 28.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+24.9%
(market-implied from PE analysis)
1-Year Target
$14.15
(+25%)
2-Year Target
$17.67
(+56%)
3-Year Target
$22.08
(+95%)
3-Yr Target (if PE normalizes)
(PE: 56â29)
PE COMPRESSION
$11.31
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 55.8, Growth: 31.3%)
$25.65
(+126%)
Base:
(SPY PE: 20.1, Growth: 31.3%)
$9.22
(-19%)
Bear:
(PE: 17.1, Growth: 31.3%)
$7.84
(-31%)
Share & Embed Analysis
Last updated: August 23, 2026 6:31 AM ET
Data refreshes hourly during market hours. Next update: 7:31 AM
Data refreshes hourly during market hours. Next update: 7:31 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 42 HOLD |
